https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-06 09:34:592024-05-07 09:35:06Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-06 09:29:572024-05-07 09:31:57Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-02 14:43:252024-05-02 14:43:25Gudrun Vogtentanz, Chief Scientific Officer at AMSilk, to speak at the Rethinking Materials Summit, 14 May 2024
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-01 08:38:152024-05-01 08:38:15Novo Holdings commits DKK 1.4 billion (€188 million) to build a quantum technology start-up ecosystem
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-01 08:35:332024-05-01 08:35:57Poolbeg Pharma plc – Significant POLB 001 Patent Granted in United States
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-30 10:53:222024-04-30 11:24:30Scientific leaders gather at global summit in Denmark to advance knowledge and solutions on health and sustainability
https://www.optimumcomms.com/wp-content/uploads/2023/06/Synox_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-30 08:05:112024-04-30 08:05:11SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-30 07:37:572024-04-30 07:37:57Poolbeg Pharma plc – Exclusive Option Agreement to Acquire Orphan Drug Candidate for Behçet’s Disease
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-30 07:33:502024-04-30 07:38:30Poolbeg Pharma – Results for the year ended 31 December 2023
https://www.optimumcomms.com/wp-content/uploads/2023/08/Bioinnovation_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-26 09:27:382024-04-26 09:27:38BII & Science launch the Translational Medicine Prize for Innovations in Women´s Health and Gender Medicine
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-25 08:34:142024-04-25 08:34:14Interim Management Statement on the First Three Months of 2024
https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-24 09:04:382024-04-25 09:04:57Calliditas Announces Positive NefIgArd Open Label Extension Results
https://www.optimumcomms.com/wp-content/uploads/2024/04/Flindr_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-24 08:22:552024-04-24 08:22:55Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors
https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-23 09:54:552024-04-23 09:54:55Vivet Therapeutics to Participate and Present at Upcoming Scientific and Investor Conferences in April through to June 2024
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-23 09:43:392024-04-23 14:22:18AMSilk strengthens management team with key hires of Ralph Fraundorfer and Ctibor Kohutovic to Management Board
https://www.optimumcomms.com/wp-content/uploads/2023/06/Synox_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-22 09:06:302024-04-22 09:06:30SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
https://www.optimumcomms.com/wp-content/uploads/2024/04/Outrun_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-18 08:38:512024-04-18 08:42:50Outrun Therapeutics launches with a $10m seed financing from M Ventures and MP Healthcare Venture Management to develop a protein stabilisation pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-18 08:36:492024-04-18 08:36:494SC publishes Q1 2024 report
https://www.optimumcomms.com/wp-content/uploads/2024/04/Xeltis_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-17 14:17:182024-04-17 14:41:42Xeltis Announces Latest Results from aXess Trials to be Presented at 46th Annual Charing Cross Symposium
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-04-15 10:51:362024-04-15 10:51:364SC AG: Paediatric Investigation Plan waiver for resminostat from the UK MHRA receivedFor more information about Optimum Strategic Communications, please get in touch.
